STRATEC proposes further dividend increase

Birkenfeld, April 9, 2015

The Supervisory Board of STRATEC Biomedical AG (Frankfurt: SBS; Prime Standard, TecDAX) at its meeting held to adopt the financial statements on April 8, 2015 approved the recommendation submitted by the Board of Management to propose the payment of a dividend of EUR 0.70 per share for the 2014 financial year for approval by the Annual General Meeting on May 22, 2015 (distribution in 2014 for the 2013 financial year: EUR 0.60). Based on the current total of 11,783,222 shares with dividend entitlement, this would correspond to a 16.9% increase in the distribution total to EUR 8.2 million (previous year: EUR 7.1 million). Shareholders can thus expect to benefit from a dividend increase for the eleventh year in succession.

The increased dividend proposal is based on the Group's earnings and cash flow performance in 2014 and its promising future prospects. Subject to approval by shareholders at the Annual General Meeting on May 22, 2015, the STRATEC Group will thus maintain its continuity-based dividend policy, involving a distribution quota of 40% to 60% of consolidated net income. STRATEC will continue to focus on external and internal growth opportunities, which may result in temporary deviations from this distribution quota. These opportunities may take the form of acquisitions or potential up-front financing for major projects.

As already announced, STRATEC will publish its audited group figures for the 2014 financial year on Tuesday, April 14, 2015.

About STRATEC
STRATEC Biomedical AG (www.stratec.com) designs and manufactures fully automated analyzer systems for its partners in the fields of clinical diagnostics and biotechnology. These partners market such systems, in general together with their own reagents, as system solutions to laboratories, blood banks and research institutes around the world. The company develops its products on the basis of its own patented technologies.
Shares in the company (ISIN: DE0007289001) are traded in the Prime Standard segment of the Frankfurt Stock Exchange and are listed in the TecDAX select index of the German Stock Exchange.

Further information can be obtained from:
STRATEC Biomedical AG
André Loy, Investor Relations
Gewerbestr. 37, 75217 Birkenfeld
Germany
Tel: +49 7082 7916-190
Fax: +49 7082 7916-999
ir@stratec.com
www.stratec.com